Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan and simvastatin combination versus monotherapy in hypertension and dyslipidemia
2005-002851-41Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telmisartan and simvastatin in hypertension (HTN) and dyslipidemia (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change from baseline to end of trial in 24-hour mean diastolic blood pressure, Change from baseline to end of trial in LDL cholesterol and 2 more. Started Dec 2005; status: completed.
02
Drugs
telmisartansimvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on 2005-002851-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002851-41.